We’ve raised a $130 million Series B led by @kleinerperkins alongside new investors @natfriedman/@danielgross , @vkhosla, and @humancapital — joined by existing investors @foundersfund , @_DimensionCap, and @brian_armstrong (yes, the cofounders are doubling down). We also raised from some of the best angels who have supported the company over the first two years including @eladgil , @garrytan , @collision, @patrickc, @JoshuaKushner, @JTLonsdale, and @FEhrsam . NewLimit is building medicines to treat aging, the meta driver of nearly every major human disease. Once thought to be irreversible, the emerging science of epigenetic reprogramming has shown that aging is in fact malleable. This presents a therapeutic opportunity that is 100X larger than any biotech product that has come before. Our bet is that this combination of AI and scaled genomics can unlock medicines that give each of us more healthy years. We're deeply appreciative of investors who share our vision that addressing aging biology represents one of the most consequential projects of humanity.